ABC | Volume 113, Nº5, November 2019

Original Article Congo et al. New-Onset atrial fibrillation in STEMI Arq Bras Cardiol. 2019; 113(5):948-957 Figure 3 – Kaplan-Meier survival curves for the two groups. 1,0 Atrial Fibrillation No Yes No-censored Yes-censored 0,8 0,6 0,4 0,2 0,0 0 20 40 60 80 100 120 140 180 Cum Survival Survival Functions Time from admission to in-hospital death (days) Table 7 – Invasive procedures performed OR (CI 95%) p Age 1.02 (1.01–1.04) p < 0.001 Prior stroke 1.87 (1.09–3.21) p = 0.023 Inferior located STEMI 1.57 (1.13–2.18) p = 0.007 Complete AV block 1.94 (1.19–3.16) p = 0.008 Values are percentage (%). AF: atrial fibrillation trial-like strategy was chosen, which is also supported by a meta-analysis that suggests that a combination of vitamin K antagonists and single antiplatelet therapy is the best choice for AF patients undergoing percutaneous coronary intervention (PCI) considering both efficacy and safety. 16,17 Stenestrand et al. 18 and Lopes et al. 15 showed that only a small percentage of patients with AF and acute MI received oral anticoagulation therapy at discharge (30% and 43.4%, respectively). Our results show a lower rate of anticoagulation: only 20.6% of patients diagnosed with AF during in-hospital stay received oral anticoagulation at discharge. Forty-five percent of patients on anticoagulation at discharge were on NOACs. Therapy with beta-blockers and angiotensin-conversion enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) was less frequently found in patients who developed new‑onset AF and although the higher incidence of complications may have limited therapeutic options, this could suggest that renin‑angiotensin-aldosterone system inhibitors and 954